Developer docs
API playgroundTry for free, no card

Search company profiles

Opthea

Full company profile

uuid00034az

Namestring
Opthea
Legal namestring
Opthea Limited
Websiteurl
opthea.com
Company typeenum
Public
Founded yearint
1984
Descriptiontext

Opthea Limited (ASX:OPT) is an Australian clinical-stage biopharmaceutical company headquartered in Melbourne with US operations in Princeton, New Jersey, focused on a single lead asset: OPT-302 (sozinibercept), a first-in-class recombinant 'trap' fusion protein comprising extracellular domains of VEGFR-3 fused to an antibody Fc fragment. The molecule binds and inhibits VEGF-C and VEGF-D, preventing activation of VEGFR-3, and is designed for combination use with anti-VEGF-A standard-of-care therapies. Opthea was historically advancing sozinibercept in wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME); following a Phase 3 wet AMD clinical trial failure in June 2026 that triggered an approximately 97% share price decline, the company relaunched as 'Opthea Reimagined' and refocused OPT-302 on lymphangioleiomyomatosis (LAM), an orphan lung disease primarily affecting women and characterised by progressive cystic destruction of the lung and abnormal lymphatic remodeling.

The business is asset-centric and pre-revenue: no products are approved or commercialised, and all operating capital has been sourced from repeated post-IPO equity placements (approximately A$90M in August 2023 and A$171.5M in June 2024), a US$90M two-tranche equity placement in August 2022, and a non-dilutive Development Funding Agreement of up to US$170M with Carlyle, Abingworth and Launch Therapeutics. The asset is supported by an extensive issued and pending patent portfolio and an existing large human safety dataset from prior wet AMD trials involving thousands of patients. Scientific credibility is anchored by a Scientific Advisory Board co-chaired by Professor Frank McCormack (founding LAM Foundation Scientific Director) and respiratory physician Deborah Yates.

Opthea's intended go-to-market model is a specialty/rare-disease commercialisation approach for LAM — concentrated engagement with KOLs, the 60+ site LAM Clinic Network, and patient-advocacy organisations such as the LAM Foundation — rather than a broad primary-care sales motion. Should sozinibercept reach approval, distribution would target hospital-based pulmonary specialists and integrated delivery networks via a focused specialty sales force. Opthea Limited is publicly listed on the ASX and files Annual Reports on Form 20-F with the U.S. SEC.

Short descriptiontext

Opthea Limited (ASX:OPT) is a pre-revenue Australian clinical-stage biopharmaceutical company developing OPT-302 (sozinibercept), a first-in-class VEGF-C/D 'trap' fusion protein, now repositioned for the orphan lung disease lymphangioleiomyomatosis (LAM) following a 2026 Phase 3 wet AMD trial failure.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSouth Yarra, Australia
HQ citystring
South Yarra
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Keyword5 values
clinical-stage biopharmaceutical, VEGF-C/D therapeutics, orphan disease biologics, recombinant fusion proteins, lymphangioleiomyomatosis treatment
Industry1 code
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Therapeutics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1None — pre-revenue
TypeLicensing Royalties
Description

Opthea is a clinical-stage biopharmaceutical company. As of the latest available material, the company has no marketed products and is not generating product revenue. Its lead asset OPT-302 (sozinibercept) is in Phase 3 clinical development (and being repositioned for the orphan disease LAM). All operating capital is sourced from equity financings and a non-dilutive Development Funding Agreement.

opthea.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Sozinibercept
Description

First-in-class VEGF-C/D 'trap' fusion protein; the lead product candidate (also known by development code OPT-302) being developed for wet AMD and, under the 'Opthea Reimagined' strategy, for lymphangioleiomyomatosis (LAM).

opthea.com
+1 more record
Core offering1 text field

Opthea is a clinical-stage biopharmaceutical company developing OPT-302 (sozinibercept), a first-in-class recombinant VEGF-C/D 'trap' fusion protein designed to inhibit VEGF-C and VEGF-D ligands before they activate VEGFR-3. Under its 'Opthea Reimagined' strategy, the company is repositioning OPT-302 as a treatment for lymphangioleiomyomatosis (LAM), an orphan lung disease, while leveraging prior human safety datasets from its earlier retinal disease program (wet AMD and DME).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • OPT-302 has already been administered to thousands of patients in prior wet AMD clinical trials, providing extensive human safety and activity datasets.
+1 more record
Product overview1 text field

Opthea Limited (ASX:OPT) is an Australian clinical-stage biopharmaceutical company operating as a single-asset-focused developer centered on one core product, OPT-302 (also known as sozinibercept), a first-in-class VEGF-C/D 'trap' fusion protein. Under the company's 'Opthea Reimagined' strategy, OPT-302 is being repositioned as the lead asset for lymphangioleiomyomatosis (LAM), an orphan lung disease, leveraging prior human safety and activity data generated when the molecule was previously investigated as a combination therapy with anti-VEGF-A standard-of-care for retinal diseases such as wet AMD. Sozinibercept combination therapy is positioned as the second named offering, representing the molecule's prior combination-therapy clinical positioning in ophthalmology; the two named products are not separate commercial franchises but rather the same molecule (OPT-302/sozinibercept) presented under its current (LAM) and prior (retinal combination-therapy) clinical framings.

Product and service1 record
1OPT-302 (sozinibercept)
CategoryLead clinical-stage biologic asset
Description

OPT-302 is a first-in-class recombinant VEGF-C/D 'trap' fusion protein that binds VEGF-C and VEGF-D to prevent activation of VEGFR-3, interrupting signaling implicated in cystic lung destruction and disease progression in LAM. The molecule comprises extracellular domains of VEGFR-3 fused with an antibody Fc fragment to extend half-life, and is intended for use alongside standard-of-care therapies. It has been administered to thousands of patients in prior wet AMD clinical trials.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Developer of ranibizumab (Lucentis), another anti-VEGF-A standard of care for wet AMD and DME, and a major ophthalmology franchise (Susvimo, Vabysmo). Direct therapeutic-area overlap with OPT-302's prior retinal combination positioning.

TypeBroad incumbent
Description

Regeneron developed Eylea (aflibercept), the leading anti-VEGF-A therapy for wet AMD and DME and the standard-of-care that OPT-302 was designed to combine with. Highly relevant comparability around the VEGF therapeutic axis and ophthalmology commercial infrastructure.

TypeDirect peer
Description

Clinical-stage ophthalmology company developing next-generation therapies for retinal diseases including wet AMD (KSI-301 / tarcocimab). Closest direct peer in the retinal combination-therapy category Opthea was competing in pre-relaunch.

TypeDirect peer
Description

Approved Syfovre for geographic atrophy and pegcetacoplan pipeline in retinal indications. Comparable late-stage retinal disease biotech profile and similar clinical development trajectory.

TypeDirect peer
Description

Commercial-stage rare-disease biotech with a focus on serious pulmonary diseases (e.g., ARIKAYCE for MAC lung disease, brensocatib for bronchiectasis). Comparable orphan/rare respiratory disease development model relevant to Opthea's LAM pivot.

TypeDirect peer
Description

Clinical-stage rare-disease focused biopharmaceutical company with a model of advancing single-mechanism assets in genetically defined diseases. Comparable single-asset orphan drug development structure and capital intensity profile.

TypeBroad incumbent
Description

Leader in RNAi-based therapeutics including Onpattro for hATTR amyloidosis, demonstrating a rare-disease commercial playbook with specialty distribution and orphan-drug pricing economics. Relevant benchmark for an orphan biologic targeting a small patient population.

TypeBroad incumbent
Description

Established rare-disease biopharma (cystic fibrosis, sickle cell) with a model of taking a single mechanistic insight into a dominant orphan franchise. Useful comparable for evaluating Opthea's LAM-focused strategy at scale.

TypeRegional player
Description

ASX-listed drug-delivery and pharmaceutical company on which Opthea NED Kathy Connell also serves as a Non-Executive Director. Regional Australian small-cap biotech peer for capital-markets and board-composition comparison rather than direct therapeutic overlap.

10Scientia Capital
TypeOthers
Description

Specialised life-sciences investment fund founded by Opthea NED Lawrence Gozlan. Included as an ecosystem/peer relationship rather than a therapeutic competitor; useful context for understanding Opthea's investor base.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Opthea

Biopharmaceutical Therapeuticsopthea.com

Opthea Limited (ASX:OPT) is a pre-revenue Australian clinical-stage biopharmaceutical company developing OPT-302 (sozinibercept), a first-in-class VEGF-C/D 'trap' fusion protein, now repositioned for the orphan lung disease lymphangioleiomyomatosis (LAM) following a 2026 Phase 3 wet AMD trial failure.

What Opthea does

Opthea Limited (ASX:OPT) is an Australian clinical-stage biopharmaceutical company headquartered in Melbourne with US operations in Princeton, New Jersey, focused on a single lead asset: OPT-302 (sozinibercept), a first-in-class recombinant 'trap' fusion protein comprising extracellular domains of VEGFR-3 fused to an antibody Fc fragment. The molecule binds and inhibits VEGF-C and VEGF-D, preventing activation of VEGFR-3, and is designed for combination use with anti-VEGF-A standard-of-care therapies. Opthea was historically advancing sozinibercept in wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME); following a Phase 3 wet AMD clinical trial failure in June 2026 that triggered an approximately 97% share price decline, the company relaunched as 'Opthea Reimagined' and refocused OPT-302 on lymphangioleiomyomatosis (LAM), an orphan lung disease primarily affecting women and characterised by progressive cystic destruction of the lung and abnormal lymphatic remodeling.

The business is asset-centric and pre-revenue: no products are approved or commercialised, and all operating capital has been sourced from repeated post-IPO equity placements (approximately A$90M in August 2023 and A$171.5M in June 2024), a US$90M two-tranche equity placement in August 2022, and a non-dilutive Development Funding Agreement of up to US$170M with Carlyle, Abingworth and Launch Therapeutics. The asset is supported by an extensive issued and pending patent portfolio and an existing large human safety dataset from prior wet AMD trials involving thousands of patients. Scientific credibility is anchored by a Scientific Advisory Board co-chaired by Professor Frank McCormack (founding LAM Foundation Scientific Director) and respiratory physician Deborah Yates.

Opthea's intended go-to-market model is a specialty/rare-disease commercialisation approach for LAM — concentrated engagement with KOLs, the 60+ site LAM Clinic Network, and patient-advocacy organisations such as the LAM Foundation — rather than a broad primary-care sales motion. Should sozinibercept reach approval, distribution would target hospital-based pulmonary specialists and integrated delivery networks via a focused specialty sales force. Opthea Limited is publicly listed on the ASX and files Annual Reports on Form 20-F with the U.S. SEC.

Opthea firmographics

Firmographics
Name
Opthea
Legal name
Opthea Limited
Website
https://opthea.com
Company type
Public
Founded year
1984
Operating status
Operating
Headcount range
11–50 employees
Short description
Opthea Limited (ASX:OPT) is a pre-revenue Australian clinical-stage biopharmaceutical company developing OPT-302 (sozinibercept), a first-in-class VEGF-C/D 'trap' fusion protein, now repositioned for the orphan lung disease lymphangioleiomyomatosis (LAM) following a 2026 Phase 3 wet AMD trial failure.
Ownership category
akta.pro rank

Opthea industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals

Keywords

  • Clinical-stage biopharmaceutical
  • VEGF-C/D therapeutics
  • Orphan disease biologics
  • Recombinant fusion proteins
  • Lymphangioleiomyomatosis treatment

Where Opthea is headquartered

Location

Headquarters

HQ city
South Yarra
HQ country
Australia
HQ region
Oceania

Markets served

Opthea business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. None — pre-revenue: Opthea is a clinical-stage biopharmaceutical company. As of the latest available material, the company has no marketed products and is not generating product revenue. Its lead asset OPT-302 (sozinibercept) is in Phase 3 clinical development (and being repositioned for the orphan disease LAM). All operating capital is sourced from equity financings and a non-dilutive Development Funding Agreement.

Go-to-market motion2 records

Marketing channels6 records

Opthea product offering

Product offering

Core offering

Opthea is a clinical-stage biopharmaceutical company developing OPT-302 (sozinibercept), a first-in-class recombinant VEGF-C/D 'trap' fusion protein designed to inhibit VEGF-C and VEGF-D ligands before they activate VEGFR-3. Under its 'Opthea Reimagined' strategy, the company is repositioning OPT-302 as a treatment for lymphangioleiomyomatosis (LAM), an orphan lung disease, while leveraging prior human safety datasets from its earlier retinal disease program (wet AMD and DME).

Product overview

Opthea Limited (ASX:OPT) is an Australian clinical-stage biopharmaceutical company operating as a single-asset-focused developer centered on one core product, OPT-302 (also known as sozinibercept), a first-in-class VEGF-C/D 'trap' fusion protein. Under the company's 'Opthea Reimagined' strategy, OPT-302 is being repositioned as the lead asset for lymphangioleiomyomatosis (LAM), an orphan lung disease, leveraging prior human safety and activity data generated when the molecule was previously investigated as a combination therapy with anti-VEGF-A standard-of-care for retinal diseases such as wet AMD. Sozinibercept combination therapy is positioned as the second named offering, representing the molecule's prior combination-therapy clinical positioning in ophthalmology; the two named products are not separate commercial franchises but rather the same molecule (OPT-302/sozinibercept) presented under its current (LAM) and prior (retinal combination-therapy) clinical framings.

Differentiator

Problem solved

Functional benefit

Brands

  • Sozinibercept: First-in-class VEGF-C/D 'trap' fusion protein; the lead product candidate (also known by development code OPT-302) being developed for wet AMD and, under the 'Opthea Reimagined' strategy, for lymphangioleiomyomatosis (LAM).
  • OPT-302

Products and services

  • OPT-302 (sozinibercept) OPT-302 is a first-in-class recombinant VEGF-C/D 'trap' fusion protein that binds VEGF-C and VEGF-D to prevent activation of VEGFR-3, interrupting signaling implicated in cystic lung destruction and disease progression in LAM. The molecule comprises extracellular domains of VEGFR-3 fused with an antibody Fc fragment to extend half-life, and is intended for use alongside standard-of-care therapies. It has been administered to thousands of patients in prior wet AMD clinical trials.

Quantifiable outcome

  • OPT-302 has already been administered to thousands of patients in prior wet AMD clinical trials, providing extensive human safety and activity datasets.
  • +1 more outcomes

Companies that use Opthea

Customer profile

Segments3 records

Ideal customer profiles2 records

Opthea technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Opthea partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Opthea competitors and assessment

Company assessment

Broad incumbents

  • Genentech (Roche): Developer of ranibizumab (Lucentis), another anti-VEGF-A standard of care for wet AMD and DME, and a major ophthalmology franchise (Susvimo, Vabysmo). Direct therapeutic-area overlap with OPT-302's prior retinal combination positioning.
  • Regeneron Pharmaceuticals: Regeneron developed Eylea (aflibercept), the leading anti-VEGF-A therapy for wet AMD and DME and the standard-of-care that OPT-302 was designed to combine with. Highly relevant comparability around the VEGF therapeutic axis and ophthalmology commercial infrastructure.
  • Alnylam Pharmaceuticals: Leader in RNAi-based therapeutics including Onpattro for hATTR amyloidosis, demonstrating a rare-disease commercial playbook with specialty distribution and orphan-drug pricing economics. Relevant benchmark for an orphan biologic targeting a small patient population.
  • Vertex Pharmaceuticals: Established rare-disease biopharma (cystic fibrosis, sickle cell) with a model of taking a single mechanistic insight into a dominant orphan franchise. Useful comparable for evaluating Opthea's LAM-focused strategy at scale.

Direct peers

  • Kodiak Sciences: Clinical-stage ophthalmology company developing next-generation therapies for retinal diseases including wet AMD (KSI-301 / tarcocimab). Closest direct peer in the retinal combination-therapy category Opthea was competing in pre-relaunch.
  • Apellis Pharmaceuticals: Approved Syfovre for geographic atrophy and pegcetacoplan pipeline in retinal indications. Comparable late-stage retinal disease biotech profile and similar clinical development trajectory.
  • Insmed: Commercial-stage rare-disease biotech with a focus on serious pulmonary diseases (e.g., ARIKAYCE for MAC lung disease, brensocatib for bronchiectasis). Comparable orphan/rare respiratory disease development model relevant to Opthea's LAM pivot.
  • BridgeBio Pharma: Clinical-stage rare-disease focused biopharmaceutical company with a model of advancing single-mechanism assets in genetically defined diseases. Comparable single-asset orphan drug development structure and capital intensity profile.

Regional players

  • Avecho Biotechnology: ASX-listed drug-delivery and pharmaceutical company on which Opthea NED Kathy Connell also serves as a Non-Executive Director. Regional Australian small-cap biotech peer for capital-markets and board-composition comparison rather than direct therapeutic overlap.

Others

  • Scientia Capital: Specialised life-sciences investment fund founded by Opthea NED Lawrence Gozlan. Included as an ecosystem/peer relationship rather than a therapeutic competitor; useful context for understanding Opthea's investor base.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Opthea social profiles

Digital presence

Opthea compliance and trust

Trust signal

Compliance1 record

Opthea financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Opthea leadership team

Management profile

Number of profiles

Profiles8 records

Opthea funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Opthea M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Opthea

What does Opthea do?

Opthea is a clinical-stage biopharmaceutical company developing OPT-302 (sozinibercept), a first-in-class recombinant VEGF-C/D 'trap' fusion protein designed to inhibit VEGF-C and VEGF-D ligands before they activate VEGFR-3. Under its 'Opthea Reimagined' strategy, the company is repositioning OPT-302 as a treatment for lymphangioleiomyomatosis (LAM), an orphan lung disease, while leveraging prior human safety datasets from its earlier retinal disease program (wet AMD and DME).

Is Opthea a public or private company?

Opthea is a public company. It is classified as public and is currently operating.

When was Opthea founded?

Opthea was founded in 1984. It employs 11 to 50 people.

Where is Opthea based?

Opthea is headquartered in South Yarra, Australia, in the Oceania region.

How does Opthea make money?

One revenue line is on record: none — pre-revenue.

Who are Opthea's main competitors?

Broad incumbents on record are Genentech (Roche), Regeneron Pharmaceuticals, Alnylam Pharmaceuticals and Vertex Pharmaceuticals. Direct peers are Kodiak Sciences, Apellis Pharmaceuticals, Insmed and BridgeBio Pharma. Avecho Biotechnology is listed as a regional player. Scientia Capital is listed as an others.

Does Opthea have an API?

No public API is recorded for Opthea.

What industry is Opthea in?

Opthea's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestFrom $29 Billion to $300 Million Written Off: How Phil King's Empire Shrunk in Seven MonthsRegal Partners wrote off its entire $300 million investment in biotech firm Opthea after the company's Phase 3 clinical trial failed, causing a significant decline in Regal's funds under management and revenue. In response to the loss, founder Phil King stepped down as manager of the flagship VG1 fund and sold over $13 million in shares, while Paul Moore assumed control of the portfolio. The event marked a contraction for Regal, which saw revenue plummet by 95% and abandoned plans to acquire Platinum Asset Management.Ophthalmology TimesOpthea parts with CEO, lays off over 80% of companyOpthea has announced a major restructuring involving the departure of CEO Fred Guerard and layoffs affecting over 80% of its workforce, following the failure of its COAST clinical trial for wet AMD. The company reached a binding agreement with DFA investors Ocelot SPV LP and Sanba II Investment Company to terminate their development funding deal, paying $20 million plus equity instead of facing potential liabilities up to $680 million. Chairman Jeremy Levin will assume additional executive responsibilities while the board conducts a strategic review over the next six months.Australian Financial ReviewInside the high-stakes gamble to revive tanked biotech OptheaOpthea, an ASX-listed biotech company, is attempting a turnaround after its late-stage clinical trials for a vision-impairment treatment failed spectacularly last year. The company is now pivoting to develop a treatment for lymphangioleiomyomatosis, a rare lung disease, with chairman Jeremy Levin seeking investor support for a second chance. Levin argues that an atmosphere of distrust is contributing to the struggles of the biotech sector overall.FoolWhy Catapult Sports, Harvey Norman, Inghams, and Opthea shares are sinking todayFour ASX-listed companies saw their share prices decline on Thursday, with Opthea experiencing the most dramatic fall at 97% after returning from a suspension caused by a clinical trial failure in retinal diseases. Harvey Norman and Inghams both declined 4-5% following broker downgrades from Macquarie Group citing concerns about consumer spending in the tough economic environment. Catapult Sports fell 6.5% with no specific news, likely driven by profit-taking after recent gains following monthly results.Business Wire BlogQlaris Bio Appoints Fred Guerard, Pharm.D., as President and Chief Executive OfficerQlaris Bio, Inc. appointed Fred Guerard as its new president and chief executive officer effective March 1, 2026, succeeding co-founder Thurein Htoo who will remain through April 1 to support the transition. The leadership change coincides with the company's advancement of its lead glaucoma therapy, QLS-111, into Phase 3 clinical development. Dr. Guerard brings extensive experience from previous roles at Opthea, Graybug Vision, and Novartis.ReutersStock Price & Latest NewsOpthea Ltd, an Australian biopharmaceutical company, is developing new treatments for vision-threatening diseases like wet AMD and DME. Its product candidate 'sozinibercept' is in Phase 3 clinical trials to evaluate efficacy when combined with standard treatments.Investing.comOpthea Halts Wet AMD Clinical Trials By Investing.comOpthea Ltd halted its Wet AMD clinical trials, as disclosed in an SEC filing. The company reported negative EBITDA of $183.2 million over the past year. The decision may shift its strategic focus, with the next earnings announcement scheduled for May 28, 2025.BenzingaOpthea Phase 3 Trial Fails To Meet Primary Endpoint, Faces Financial UncertaintyOpthea Limited released results from its global Phase 3 clinical trial COAST for wet age-related macular degeneration, which did not meet its primary endpoint of mean change in best corrected visual acuity at week 52, showing no statistical difference between sozinibercept combination therapy and Regeneron's Eylea monotherapy. Following the negative results, Opthea is reviewing its obligations under its Development Funding Agreement and could face payment obligations of up to $680 million to investors who hold a lien on all company assets. The company has requested trading suspension on both ASX and Nasdaq amid significant uncertainty about its ability to continue operating.Daily Medical NewsPhase 3 COAST trial of wet AMD combination therapy misses primary endpointThe phase 3 COAST trial of sozinibercept plus aflibercept for wet AMD missed its primary endpoint. At week 52, aflibercept monotherapy improved best-corrected visual acuity by 13.8 letters, while the combination therapy improved it by 13.5 letters overall. Opthea may owe DFA investors up to four multiples of amounts paid under the agreement.GlobeNewswireOpthea Appoints Kathy Connell to Board of DirectorsOpthea appointed Kathy Connell as non-executive director, effective after its November 15, 2024 annual general meeting. The appointment comes as the company prepares for the topline data readout of its sozinibercept Phase 3 trials in wet AMD in 2025.